Could resTORbio, Inc. (TORC) Go Down? The Stock Formed Bearish Double Bottom

August 10, 2018 - By Rene Reddy

The chart of resTORbio, Inc. (TORC) shows a double bottom with $10.65 target or 6.00 % below today’s $11.33 share price. The 8 months chart pattern indicates high risk for the $317.77 million company. It was reported on Aug, 10 by Finviz.com. If the $10.65 price target is reached, the company will be worth $19.07 million less. Double bottoms are rare but powerful chart patterns.

It closed at $11.33 lastly. It is down 0.00% since August 10, 2017 and is . It has underperformed by 12.57% the S&P500.

More notable recent resTORbio, Inc. (NASDAQ:TORC) news were published by: Nasdaq.com which released: “resTORbio to Present at the Canaccord Genuity 38th Annual Growth Conference” on July 30, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on August 01, 2018, Globenewswire.com published: “resTORbio Reports Second Quarter 2018 Financial Results” on August 09, 2018. More interesting news about resTORbio, Inc. (NASDAQ:TORC) were released by: Nasdaq.com and their article: “Mid-Afternoon Market Update: US Stocks Turn Higher; Travelzoo Shares Slide” published on July 25, 2018 as well as Nasdaq.com‘s news article titled: “Why resTORbio, Inc. Stock Skyrocketed Today” with publication date: July 25, 2018.

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. The company has market cap of $317.77 million. The Company’s lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. It currently has negative earnings. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system.

resTORbio, Inc. (NASDAQ:TORC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.